Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.
Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, Roses RE, Czerniecki BJ. Lowenfeld L, et al. Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13. Clin Cancer Res. 2017. PMID: 27965306 Clinical Trial.
Optimizing dendritic cell-based approaches for cancer immunotherapy.
Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Datta J, et al. Among authors: lowenfeld l. Yale J Biol Med. 2014 Dec 12;87(4):491-518. eCollection 2014 Dec. Yale J Biol Med. 2014. PMID: 25506283 Free PMC article. Review.
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ. Datta J, et al. Among authors: lowenfeld l. Breast Cancer Res. 2015 May 23;17(1):71. doi: 10.1186/s13058-015-0584-1. Breast Cancer Res. 2015. PMID: 25997452 Free PMC article.
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.
Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ. Lowenfeld L, et al. Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017. Oncoimmunology. 2016. PMID: 28932627 Free PMC article.
Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.
Rosemblit C, Datta J, Lowenfeld L, Xu S, Basu A, Kodumudi K, Wiener D, Czerniecki BJ. Rosemblit C, et al. Among authors: lowenfeld l. Oncotarget. 2018 May 1;9(33):23058-23077. doi: 10.18632/oncotarget.25208. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796172 Free PMC article.
CD4+ Th1 to the rescue in HER-2+ breast cancer.
Lowenfeld L, Xu S, Czerniecki BJ. Lowenfeld L, et al. Oncoimmunology. 2018 May 2;8(10):e1078062. doi: 10.1080/2162402X.2015.1078062. eCollection 2019. Oncoimmunology. 2018. PMID: 31646065 Free PMC article.
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.
Kasi PM, Hidalgo M, Jafari MD, Yeo H, Lowenfeld L, Khan U, Nguyen ATH, Siolas D, Swed B, Hyun J, Khan S, Wood M, Samstein B, Rocca JP, Ocean AJ, Popa EC, Hunt DH, Uppal NP, Garrett KA, Pigazzi A, Zhou XK, Shah MA, Hissong E. Kasi PM, et al. Among authors: lowenfeld l. Oncogene. 2023 Oct;42(44):3252-3259. doi: 10.1038/s41388-023-02835-y. Epub 2023 Sep 21. Oncogene. 2023. PMID: 37731056 Free PMC article.
17 results